Technology
Health
Biotechnology

MacroGenics

$18.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.14 (-0.74%) Today
-$0.14 (-0.74%) Today

Why Robinhood?

You can buy or sell MacroGenics and other stocks, options, ETFs, and crypto commission-free!

About

MacroGenics, Inc. Common Stock, also called MacroGenics, is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Read More 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Employees
364
Headquarters
Rockville, Maryland
Founded
2000
Market Cap
800.05M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
498.26K
High Today
$19.01
Low Today
$18.75
Open Price
$18.91
Volume
12.19K
52 Week High
$30.05
52 Week Low
$9.87

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Therapy
Cancer Prevention
Pharmaceutical

News

MarketBeatMar 8

Stock Price, News, & Analysis for MacroGenics

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, and autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It is also d...

43
The Motley FoolFeb 27

Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript

Macrogenics Inc (NASDAQ:MGNX) Q4 2018 Earnings Conference Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon. We will begin the MacroGenics 2018 Fourth Quarter and Full Year Corporate Progress and Financial Results Conference Call in just a moment. All participants are in listen-only mode at the moment and we will conduct a question-and-answer session at the conclusion of the call. At this point, I will turn the call over...

31
Simply Wall StFeb 23

Should You Be Pleased About The CEO Pay At MacroGenics, Inc.’s (NASDAQ:MGNX)

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Scott Koenig has been the CEO of MacroGenics, Inc. (NASDAQ:MGNX) since 2001. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider the growth in the business. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. This method should give us information to assess...

5

Earnings

-$1.34
$0.09
$1.53
$2.96
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.